Get the Stockscreener App
0.00
100.00%
-0.765
After Hours:
.75
0.75
+
Genetic Technologies Ltd Adr stock is traded at $0.00, with a volume of 0.
It is down -100.00% in the last 24 hours and down -100.00% over the past month.
Genetic Technologies Ltd is an Australia-based molecular diagnostics company that offers predictive testing and assessment tools to help physicians proactively manage women's health. The company has developed BREVAGenplus which is a clinically validated risk assessment test for non-hereditary breast cancer. It also provides genetic testing services including medical testing, animal testing, forensic testing, and plant testing. The company markets BREVAGenplus to healthcare professionals in breast healthcare and imaging centers, as well as to obstetricians/ gynecologists (OBGYNs) and breast cancer risk assessment specialists. The majority of the company's revenue is generated from Australia and the United States. The group has two operating segments: EasyDNA and GeneType/Corporate.
See More
Previous Close:
$0.765
Open:
$0
24h Volume:
0
Relative Volume:
0.00
Market Cap:
$3.71M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
0.00
EPS:
-0.604
Net Cash Flow:
-
1W Performance:
-100.00%
1M Performance:
-100.00%
6M Performance:
-100.00%
1Y Performance:
-100.00%
1-Day Range:
$0.00
$0.00
1-Week Range:
$0.00
$0.00
52-Week Range:
$0.00
$3.59
Genetic Technologies Ltd Adr Stock (GENE) Company Profile
Name
Genetic Technologies Ltd Adr
Sector
Industry
Phone
-
Address
-
Compare GENE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GENE
Genetic Technologies Ltd Adr
|
0.00 | 3.71M | 0 | 0 | 0 | 0.00 |
|
TMO
Thermo Fisher Scientific Inc
|
580.57 | 222.07B | 42.88B | 6.34B | 7.27B | 16.53 |
|
DHR
Danaher Corp
|
215.01 | 154.61B | 23.88B | 3.90B | 5.30B | 5.28 |
|
A
Agilent Technologies Inc
|
147.04 | 41.95B | 6.51B | 1.29B | 1.37B | 4.42 |
|
IDXX
Idexx Laboratories Inc
|
465.03 | 38.08B | 3.84B | 866.24M | 792.60M | 10.37 |
|
IQV
Iqvia Holdings Inc
|
200.04 | 36.31B | 15.32B | 1.41B | 1.96B | 7.62 |
Genetic Technologies Ltd Adr Stock (GENE) Latest News
SOHM, Inc. Secures Key Patent for Revolutionary Gene Editing Technology - Sangri Today Spotlight
Genetic Technologies files regulatory report - Investing.com India
Genetic Technologies appoints voluntary administrators By Investing.com - Investing.com South Africa
Genetic Technologies appoints voluntary administrators - Investing.com India
10 Biggest Biotechnology Companies - Investopedia
Japan Plasmid DNA Manufacturing Market Size & Outlook, 2030 - Grand View Research
Middle East & Africa Plasmid DNA Manufacturing Market Size & Outlook, 2030 - Grand View Research
Genetic Technologies faces NASDAQ equity shortfall - Investing.com India
Genetic Technologies joins "CancerIQ" platform - Investing.com
Stocks of the Hour: DroneShield, Genetic Technologies, Cauldron Energy - ShareCafe
Genetic Technologies faces Nasdaq noncompliance issue - Investing.com
Genetic Technologies faces Nasdaq noncompliance issue By Investing.com - Investing.com UK
Genetic Technologies launches geneType on EasyDNA platform - Investing.com
Ascendis Pharma (ASND) Surges 8.7%: Is This an Indication of Further Gains? - Yahoo Finance
India Pancreatic Cancer Diagnostic Market Size & Outlook, 2030 - Grand View Research
India Plasmid DNA Manufacturing Market Size & Outlook, 2030 - Grand View Research
China Hereditary Testing Market Size & Outlook, 2023-2030 - Grand View Research
Anocca AB Licenses Gene Editing Technology from EmendoBio Inc. - Yahoo Finance
6 Best Genomics Stocks to Buy in 2024 - The Motley Fool
A pharmacogenetic study of perampanel: association between rare variants of glutamate receptor genes and outcomes - Frontiers
Genetic Technologies Limited Announces Ordinary Share Consolidation and ADS Ratio Change - Yahoo Finance
Check Up: How supramolecular technology is used in biotech, and why L’Oréal wants to get its hands on it - Stockhead
Check Up: Biotech is worth ‘US$4 trillion in 10 years’, and here’s where the smart money ... - Stockhead
Alexion, AstraZeneca Rare Disease, enters agreement with Pfizer to acquire a portfolio of preclinical rare disease gene therapies - AstraZeneca
Check Up: Almost half a billion US dollars raised to bring back mammoth, dodo, and Tassie tiger - Stockhead
Syncona to acquire Applied Genetic Technologies Corporation - BioPharma-Reporter.com
Le 1001 azioni che si sono schiantate sul mercato azionario USA - Scenari Economici
Start of demonstration experiment of algal breeding technology to solve climate change issues -Aiming to establish the world's first useful algae breeding technology by introducing genetic mutation through neutron irradiation- - NTT
Tech - GSK
Pharmacogenomics Market Size, Share & Growth Report 2032 - P&S Intelligence
Check up: 78 biotech companies rocked the boat this week but only one has real news - Stockhead
Genetic Technologies Ltd.ADR Shares Fall 0.8% Below Previous 52-Week LowMarket Mover - Nasdaq
MOU between MPUAT and Sona Genetics Pvt. Limited, Ahmedabad - Krishak Jagat English
The Daily Biotech Pulse: Novartis Funding For Gene Therapy Research, Priority Review For Amgen Cancer Drug, Pfizer-BioNTech Vaccine Supply Deal - Yahoo Finance
The Daily Biotech Pulse: DermTech Soars On Contract, Fluidigm Plunges On Earnings, Decision Day For Regeneron, Bioventus Debuts - Benzinga
The Daily Biotech Pulse: Pfizer's Eczema Drug Aces Latestage Study, Orphan Drug Designation For Dicerna, Dyadic's COVID-19 Connection - Yahoo Finance
6 ASX BioTechs Trading on the NASDAQ - TheBull.com.au
Why XOMA Corp. (Nasdaq: XOMA) Stock Jumped 24.4% in One Day - Money Morning
BioMarin is a global biotechnology company with eight marketed products that treat life-threatening conditions. - BioMarin Pharmaceutical Inc.
Former Genetic Technologies chief jailed for market manipulation; Merry Christmas ahead for property buyers at auctions: Midday Roundup - SmartCompany
Brazilian telcos higher on merger talk - MarketWatch
Pfizer: One of the world's premier biopharmaceutical companies - Pfizer
GTG lists on Nasdaq national market - Lab + Life Scientist
Genetic Technologies Ltd Adr Stock (GENE) Financials Data
There is no financial data for Genetic Technologies Ltd Adr (GENE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
5.26%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):